Bristol To Submit Ixabepilone In First Half Of 2007 For Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Firm reports statistically significant Phase III data for ixabepilone/Xeloda combination at American Society of Clinical Oncology meeting in Chicago.
You may also be interested in...
Regulatory action on the epothilone B analog is anticipated in October, Bristol says.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.